Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.North Carolina-based pharmaceutical firm Pozen Inc has been issued a European patent covering its proprietary treatment, a combination of a triptan and a non-steroidal anti-inflammatory drug, for migraine.
Subscribe to our email newsletter
The European patent designates 18 countries in Europe and is in addition to similar patents issued to Pozen in the US and Australia. Equivalent patent applications are pending in Canada and Japan.
Pozen is collaborating with GlaxoSmithKline in the development of the product for the US market. Trexima is the proposed brand name for the product, a single tablet containing sumatriptan succinate, a 5-HT 1B/1D agonist, and naproxen sodium, a non-steroidal anti-inflammatory drug (NSAID).
Since its inception, Pozen has focused its efforts primarily on the development of pharmaceutical products for the treatment of migraine, a multi-billion dollar global market. However, the company is also exploring the development of product candidates in other pain-related therapeutic areas.
Pozen has development and commercial alliances with GlaxoSmithKline, Xcel Pharmaceuticals, and Nycomed and has helped in the development and approval of over 40 drugs.